136869-07-3

Basic information

• Product Name: N-[4-(hydroxymethyl)benzyl]acetamide
• Synonyms: acetamide, N-[[4-(hydroxymethyl)phenyl]methyl]-
• CAS NO: 136869-07-3
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.2157
• Mol File: 136869-07-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 426.2°C at 760 mmHg
• Flash Point: 211.5°C
• Density: 1.13g/cm³
• Vapor Pressure: 5.05E-08mmHg at 25°C
• Refractive Index: 1.55
• CAS DataBase Reference: N-[4-(hydroxymethyl)benzyl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(hydroxymethyl)benzyl]acetamide(136869-07-3)
• EPA Substance Registry System: N-[4-(hydroxymethyl)benzyl]acetamide(136869-07-3)

Safety Data

• Hazardous Substances Data: 136869-07-3(Hazardous Substances Data)

Upstream product

• 105-07-7 4-cyanobenzaldehyde 
• 39895-56-2 4-hydroxymethyl-benzylamine 
• 1129-35-7 4-cyanobenzoic acid methyl ester 
• 18469-52-8 methyl 4-(aminomethyl)benzoate 
• 100390-63-4 4-(acetamidomethyl)benzyl acetate 
• 20686-40-2 4-(acetylamino-methyl)-benzoic acid methyl ester 
• 874-89-5 4-Cyanobenzyl alcohol 
• 1205-58-9 4-[(Acetylamino)methyl]-benzoic acid 
• 56-91-7 p-aminomethylbenzoic acid 
• 108-24-7 acetic anhydride 

Downstream Products

• 223512-41-2 N-(4-chloromethyl-benzyl)-acetamide 
• 223512-42-3 N-(4-((4-phenylpiperazin-1-yl)methyl)phenylmethyl)acetamide 
• 223511-24-8 N-(4-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)phenylmethyl)acetamide 
• 132719-04-1 {4-[(methylamino)methyl]phenyl}methanol 
• 1373162-35-6 C₂₆H₂₂Cl₂N₄O₆S₄ 
• 1192815-20-5 N-(4-(bromomethyl)benzyl)acetamide 

Relevant articles and documents

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

Piperazine compounds and medicinal use thereof

The present invention relates to a piperazine compound of the formula wherein R1and R2are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4and R5are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6and R7are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8and R9are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-α production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-α production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-α production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-α mediated diseases.